Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROSTAT vs MONOKET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that releases nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation. Preferentially dilates coronary arteries and veins, reducing preload and afterload.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Acute relief of angina pectoris,Prophylaxis of angina pectoris before activities that may provoke an attack,Off-label: Treatment of acute heart failure, hypertensive urgency
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
0.3-0.6 mg sublingually or buccally every 5 minutes as needed for angina relief, up to a maximum of 3 doses in 15 minutes.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
2–3 minutes for initial distribution phase; terminal elimination half-life is approximately 1–4 minutes. Rapid clearance due to extensive metabolism in the liver and other tissues (via glutathione-organic nitrate reductase).
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Rapidly metabolized in the liver by glutathione-organic nitrate reductase and by erythrocytes; CYP450 not primarily involved.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Renal excretion of inactive metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for about 35%. Unchanged nitroglycerin is minimally excreted in urine (<1%).
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Approximately 60% bound to plasma proteins (albumin and possibly others).
Isosorbide mononitrate is less than 5% bound to plasma proteins.
3–4 L/kg, indicating extensive distribution into tissues, particularly vascular smooth muscle and other highly perfused organs.
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Sublingual: 30–60% (bypasses first-pass hepatic metabolism). Oral: <10% due to extensive first-pass metabolism. Transdermal: 10–20% depending on formulation and application site. Intravenous: 100%.
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
No dosage adjustment required for renal impairment; use with caution in patients with severe renal impairment due to potential for hypotension.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Caution, consider dose reduction; Child-Pugh Class C: Avoid use due to increased risk of methemoglobinemia.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Not recommended for use in children due to lack of safety and efficacy data.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Initiate at lower end of dosing range (0.3 mg) due to increased sensitivity to vasodilation and higher risk of hypotension; monitor closely.
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) as this can cause severe hypotension, syncope, or myocardial ischemia.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension and reflex tachycardia may occur,May exacerbate angina due to excessive hypotension,Tolerance may develop with prolonged use,Abrupt discontinuation may precipitate angina
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Hypersensitivity to nitroglycerin,Concurrent use of phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe hypotension (systolic BP <90 mm Hg),Cardiac tamponade, constrictive pericarditis, or restrictive cardiomyopathy,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage)
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
Avoid alcohol, which can enhance hypotensive effects and cause severe dizziness or fainting. Grapefruit juice may increase nitroglycerin absorption and risk of adverse effects. No other significant food interactions.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
FDA Pregnancy Category C. Nitroglycerin crosses the placenta. Animal studies show no teratogenic effects. Use in first trimester only if clearly needed; second/third trimester: risk of fetal bradycardia and hypotension. Avoid near term due to potential for maternal hypotension and reduced uterine blood flow.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
Nitroglycerin is excreted into breast milk in small amounts; M/P ratio unknown. No known adverse effects in infants. Use with caution, especially in nursing of premature or ill infants.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
No specific dose adjustment required for pregnancy; however, due to increased plasma volume and altered hemodynamics, monitor efficacy and titrate to response. Use lowest effective dose to minimize maternal hypotension.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
Nitroglycerin sublingual tablets (Nitrostat) are first-line for acute angina. Store in original glass bottle, tightly closed; potency degrades with exposure to light, heat, and moisture. Patients should feel a tingling or burning sensation under the tongue—if absent, tablet may be ineffective. Administer 0.3-0.6 mg at first sign of angina; may repeat every 5 minutes up to 3 doses. If pain persists after 3 doses, seek emergency care. Contraindicated with recent use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Hypotension and reflex tachycardia are common; monitor blood pressure. Tolerance develops with sustained use; use minimal effective dose and allow nitrate-free interval (10-12 hours daily) for long-acting forms.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Take at the first sign of chest pain; do not wait for severe pain.,Place the tablet under the tongue or between the cheek and gum; do not swallow or chew.,Sit or lie down when taking to avoid dizziness or fainting from low blood pressure.,If no relief after 5 minutes, repeat one dose; if still no relief after 3 doses in 15 minutes, call 911 immediately.,Store in the original glass bottle, tightly closed, away from heat and light; do not store in bathroom or kitchen.,Replace the bottle 6 months after opening, as the medication loses potency.,Do not drink alcohol while taking this medication; it can cause severe hypotension.,Do not take with erectile dysfunction drugs (Viagra, Cialis, Levitra) as it can cause a fatal drop in blood pressure.,Avoid grapefruit juice as it may increase side effects.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROSTAT vs MONOKET, answered by our medical review team.
NITROSTAT is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that releases nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation. Preferentially dilates coronary arteries and veins, reducing preload and afterload.. MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROSTAT and MONOKET depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROSTAT is: 0.3-0.6 mg sublingually or buccally every 5 minutes as needed for angina relief, up to a maximum of 3 doses in 15 minutes.. The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROSTAT and MONOKET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROSTAT is classified as Category C. FDA Pregnancy Category C. Nitroglycerin crosses the placenta. Animal studies show no teratogenic effects. Use in first trimester only if clearly needed; second/third trimester: ris. MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.